Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 15/20 | 0.70 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21938111 | 0.88 | CREBBP (0.65) | CREBBPLPAR1 | |
| SCHEMBL20532149 | 0.83 | CREBBP (1.00) | CREBBPBRD4PTGS2 | |
| SCHEMBL21937961 | 0.82 | CREBBP (0.67) | CREBBPBRD4PTGS2LPAR1 | |
| SCHEMBL9955454 | 0.82 | LPAR1 (0.47) | CREBBPPTGS2LPAR1NPC1HSP90AA1 | |
| SCHEMBL21938200 | 0.82 | CREBBP (0.74) | CREBBPBRD4PTGS2NPC1HSP90AA1 | |
| SCHEMBL27094645 | 0.77 | CREBBP (0.65) | CREBBPBRD4 | |
| SCHEMBL20532429 | 0.74 | CREBBP (0.63) | CREBBPBRD4 | |
| SCHEMBL20531966 | 0.73 | CREBBP (0.60) | CREBBPBRD4 | |
| SCHEMBL21937920 | 0.73 | CREBBP (0.64) | CREBBP | |
| SCHEMBL9697757 | 0.73 | PKM (0.41) | CREBBPBRD4LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-11020380-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10617680-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020380-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | CREBBP 18/4885BRD4 2/4885PTGS2 2216/4885 |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | CREBBP 18/4885BRD4 2/4885PTGS2 2216/4885 |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | CREBBP 18/4885BRD4 2/4885PTGS2 2216/4885 |
| US-10617680-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | CREBBP 18/4885BRD4 2/4885PTGS2 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.